Pharmaceuticals, Biotechnology and Life Sciences
Amgen and UCB said Friday that Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has re-examined and recommended Marketing Authorization for Evenity (romosozumab) for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture and with no history of myocardial infarction or stroke.
FREIENBACH, Switzerland–(BUSINESS WIRE)—-EffRx Pharmaceuticals SA is proud to announce that it will participate in the 19th Edition of the World…
Amgen and UCB on Tuesday reported getting licence to market Evenity to treat patients with osteoporosis, who have high risk…
Alvogen and Pfenex have signed a deal which grants Alvogen exclusive rights to commercialize Pfenex’s lead drug candidate, PF708, a…
Eli Lilly has reported new data showing that treatment with FORTEO for 24 months was associated with significantly fewer vertebral and clinical…
Men face a greater risk of mortality following a fracture related to osteoporosis, a common disease where the bones become weak and brittle